CYT387, a potent IKBKE inhibitor, suppresses human glioblastoma progression by activating the Hippo pathway
Open Access
- 20 September 2021
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 19 (1) , 1-15
Abstract
Recent studies have showed that IKBKE is overexpressed in several kinds of cancers and that IKBKE-knockdown inhibits tumor progression. In this article, we first verified that two glioblastoma cell lines, U87-MG and LN-229, were sensitive to CYT387 by measuring the half maximal inhibitory concentration (IC50) with a CCK-8 assay and then demonstrated that CYT387, as a potent IKBKE inhibitor, suppressed glioblastoma cell proliferation, migration and invasion. Additionally, CYT387 induced cell apoptosis and arrested the cell cycle at the G2/M checkpoint in vitro. Furthermore, we showed that CYT387 did not simply inhibit IKBKE activity but also decreased IKBKE expression at the protein level rather than at the mRNA level. We discovered that CYT387 restrained malignant tumor progression by activating the Hippo pathway in vitro. By coimmunoprecipitation (co-IP), we showed that IKBKE interacted with TEAD2 and YAP1, thus accelerating TEAD2 and YAP1 transport into the nucleus. In subsequent in vivo experiments, we found that CYT387 inhibited subcutaneous nude mouse tumor growth but had little impact on intracranial orthotopic xenografts, probably due to a limited ability to penetrate the blood–brain barrier (BBB). These results suggest that CYT387 has potential as a new antiglioblastoma drug, but an approach to allow passage through the blood–brain barrier (BBB) is needed.Keywords
Funding Information
- National Natural Science Foundation of China (81572490, 81172405)
This publication has 49 references indexed in Scilit:
- IKBKE Phosphorylation and Inhibition of FOXO3a: A Mechanism of IKBKE Oncogenic FunctionPLOS ONE, 2013
- Kinome expression profiling identifies IKBKE as a predictor of overall survival in clear cell renal cell carcinoma patientsCarcinogenesis, 2012
- Yes-Associated Protein 1 Is Widely Expressed in Human Brain Tumors and Promotes Glioblastoma GrowthJournal of Neuropathology & Experimental Neurology, 2011
- A single NFκB system for both canonical and non-canonical signalingCell Research, 2010
- AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinomaOncogene, 2010
- Evidence for a Growth-Stabilizing Regulatory Feedback Mechanism between Myc and Yorkie, the Drosophila Homolog of YapDevelopmental Cell, 2010
- TEAD Transcription Factors Mediate the Function of TAZ in Cell Growth and Epithelial-Mesenchymal TransitionJournal of Biological Chemistry, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Phosphorylation of the Tumor Suppressor CYLD by the Breast Cancer Oncogene IKKɛ Promotes Cell TransformationMolecular Cell, 2009
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005